MMV and sanofi-aventis launch ambitious antimalarial monitoring programme

Ambitious drug-monitoring program started in Africa

19 Nov 2009

MMV and sanofi-aventis have have joined forces to conduct the largest safety and efficacy study of an antimalarial drug. This field-monitoring program on ASAQ, a fixed-dose combination of artesunate and amodiaquine, commenced in Côte d’Ivoire in October 2009.